Tern’s Bruce Leith appointed Executive Chairman of Purple Transform

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IOT) technology businesses, has announced that Bruce Leith, the Company’s Business Development Director, a non-board position, has been appointed as Executive Chairman of Purple Transform Limited.  Tern will be paid the fees for Bruce Leith’s services.

Purple Transform is a company that Sure Valley Ventures Enterprise Capital LP (SVV2) is invested in.  As announced on 2 March 2022, Tern has previously committed to invest up to £5 million in SVV2 over the 10-year life of SVV2. Tern has a 6.1% holding in SVV2.

Commenting, Ian Richie, Chairman of Tern, said: “As I have previously stated, Tern’s focus is on realisations, but we will take appropriate opportunities to utilise the skills and experience of the Tern team’s hands on approach to generate income for Tern, without detracting from our primary purpose.  Bruce’s appointment to assist Purple Transform will not only provide a modest income stream for Tern, but it is intended to help drive value creation in the Purple Transform business that Tern will benefit from through its holding in SVV2.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search